DK115591D0 - Pneumolysinmutanter og pneumokokvacciner fremstillet deraf - Google Patents

Pneumolysinmutanter og pneumokokvacciner fremstillet deraf

Info

Publication number
DK115591D0
DK115591D0 DK911155A DK115591A DK115591D0 DK 115591 D0 DK115591 D0 DK 115591D0 DK 911155 A DK911155 A DK 911155A DK 115591 A DK115591 A DK 115591A DK 115591 D0 DK115591 D0 DK 115591D0
Authority
DK
Denmark
Prior art keywords
mutants
pneumolyminutants
pneumococvaccines
prepared
pneumolysin
Prior art date
Application number
DK911155A
Other languages
English (en)
Other versions
DK173629B1 (da
DK115591A (da
Inventor
James Cleland Paton
David John Hansman
Graham John Boulnois
Peter William Andrew
Timothy John Mitchell
John Arthur Walker
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of DK115591D0 publication Critical patent/DK115591D0/da
Publication of DK115591A publication Critical patent/DK115591A/da
Application granted granted Critical
Publication of DK173629B1 publication Critical patent/DK173629B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Current-Collector Devices For Electrically Propelled Vehicles (AREA)
DK199101155A 1988-12-16 1991-06-14 Ændret pneumolysin, vaccine indeholdende det ændrede pneumolysin, rekombinant plasmid, som koder for det ændrede pneumolysin, hybrid værtscelle indeholdende det rekombinante plasmid, metoder til fremstilling af det ændrede........ DK173629B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPJ198988 1988-12-16
AUPJ198988 1988-12-16
PCT/AU1989/000539 WO1990006951A1 (en) 1988-12-16 1989-12-15 Pneumolysin mutants and pneumococcal vaccines made therefrom
AU8900539 1989-12-15

Publications (3)

Publication Number Publication Date
DK115591D0 true DK115591D0 (da) 1991-06-14
DK115591A DK115591A (da) 1991-08-14
DK173629B1 DK173629B1 (da) 2001-05-14

Family

ID=3773589

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199101155A DK173629B1 (da) 1988-12-16 1991-06-14 Ændret pneumolysin, vaccine indeholdende det ændrede pneumolysin, rekombinant plasmid, som koder for det ændrede pneumolysin, hybrid værtscelle indeholdende det rekombinante plasmid, metoder til fremstilling af det ændrede........

Country Status (15)

Country Link
EP (1) EP0449856B1 (da)
JP (1) JP3237842B2 (da)
AT (1) ATE205534T1 (da)
AU (1) AU626961B2 (da)
BG (1) BG51358A3 (da)
CA (1) CA2005704C (da)
DE (1) DE68929323T2 (da)
DK (1) DK173629B1 (da)
ES (1) ES2160570T3 (da)
FI (1) FI103122B1 (da)
HU (1) HUT58804A (da)
MC (1) MC2178A1 (da)
NO (1) NO304317B1 (da)
RU (1) RU2121481C1 (da)
WO (1) WO1990006951A1 (da)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5391712A (en) * 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
WO1995016711A1 (es) * 1993-12-17 1995-06-22 Universidad De Oviedo Anticuerpos contra la neumolisina y sus aplicaciones
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
AU740956B2 (en) * 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
HU228499B1 (en) * 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
DK2395073T3 (da) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Fremgangsmåde til tørring.
CA2504938C (en) * 2002-11-07 2011-10-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
DE602004010376T2 (de) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
PL1648500T3 (pl) 2003-07-31 2014-12-31 Novartis Vaccines & Diagnostics Inc Kompozycje immunogenne dla Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
CA2555803A1 (en) * 2004-02-13 2005-08-27 Sanofi Pasteur Limited Pneumolysin derivatives
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (en) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
JP2008544949A (ja) 2004-10-08 2008-12-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 化膿性レンサ球菌のための免疫激性組成物および治療用組成物
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
LT3017827T (lt) 2005-12-22 2019-01-10 Glaxosmithkline Biologicals S.A. Pneumokokinė polisacharidinė konjuguota vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
EP2386567B1 (en) * 2007-04-13 2014-10-29 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
RU2471497C2 (ru) 2007-09-12 2013-01-10 Новартис Аг Мутантные антигены gas57 и антитела против gas57
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
JP5749642B2 (ja) 2008-04-16 2015-07-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
KR101741426B1 (ko) * 2008-12-24 2017-05-30 더 킹덤 오드 더 네덜란드, 레프리젠티드 바이 더 미니스트리 오브 헬스, 웰페어 앤드 스포츠, 온 비하프 오브 더 미니스터, 더 내셔널 인스티튜트 포 퍼블릭 헬스 앤드 디 인바이런먼트 변형된 스트렙토코커스 뉴모니아 뉴몰리신(ｐｌｙ) 폴리펩타이드
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
AU2010335970B2 (en) * 2009-12-22 2016-11-03 Sanofi Pasteur Limited Immunogenic compositions
ES2651005T3 (es) 2010-03-09 2018-01-23 Biomedical Research Models, Inc. Una nueva estrategia de vacunación mucosa para el virus del herpes simple tipo-2
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
AU2014203873A1 (en) 2013-01-07 2015-07-30 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
WO2014186796A1 (en) 2013-05-17 2014-11-20 The Board Of Regents Of The University Of Texas System Immunization to protect against adverse cardiac events relating to pneumococcal infection
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
AU2015349787B2 (en) 2014-11-21 2021-07-29 The Board Of Regents Of The University Of Oklahoma Pneumolysin mutants and methods of use thereof
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
CN109562057A (zh) 2016-05-16 2019-04-02 传染病研究所 聚乙二醇化脂质体和使用方法
BR112018074352B1 (pt) 2016-06-01 2021-11-30 Infectious Disease Research Institute Partículas de nanoalume contendo um agente de dimensionamento
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
BR112020021271A2 (pt) 2018-04-17 2021-01-26 Celldex Therapeutics, Inc. construtos bispecíficos e anticorpos anti- cd27 e anti-pd-l1
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
IL312890A (en) 2021-11-18 2024-07-01 Matrivax Inc Immunogenic fusion protein preparations and methods of using them
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Also Published As

Publication number Publication date
ATE205534T1 (de) 2001-09-15
EP0449856A4 (en) 1992-05-20
DE68929323T2 (de) 2002-04-18
DK173629B1 (da) 2001-05-14
ES2160570T3 (es) 2001-11-16
NO912226D0 (no) 1991-06-11
MC2178A1 (fr) 1992-05-22
AU4756490A (en) 1990-07-10
RU2121481C1 (ru) 1998-11-10
DE68929323D1 (de) 2001-10-18
WO1990006951A1 (en) 1990-06-28
EP0449856B1 (en) 2001-09-12
CA2005704A1 (en) 1990-06-16
BG51358A3 (en) 1993-04-15
NO304317B1 (no) 1998-11-30
DK115591A (da) 1991-08-14
FI103122B (fi) 1999-04-30
NO912226L (no) 1991-07-25
EP0449856A1 (en) 1991-10-09
FI912878A0 (fi) 1991-06-14
FI103122B1 (fi) 1999-04-30
HUT58804A (en) 1992-03-30
CA2005704C (en) 2003-02-11
JPH04503948A (ja) 1992-07-16
JP3237842B2 (ja) 2001-12-10
AU626961B2 (en) 1992-08-13

Similar Documents

Publication Publication Date Title
DK115591D0 (da) Pneumolysinmutanter og pneumokokvacciner fremstillet deraf
NO894614D0 (no) Hudtest og testkit for aids.
IL115047A (en) Immunogenic conjugates comprising pneumococcal polysaccharide and recombinant pneumolysin, vaccines comprising such conjugates and use of such vaccines in the manufacture of medicaments for immunizing against pneumococcal infections
WO1999003884A3 (en) Modified immunogenic pneumolysin, compositions and their use as vaccines
ZA91559B (en) Vaccines against cancer and infectious diseases
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ATE229978T1 (de) Helicobacter proteine und impstoffe
PL291855A1 (en) Method of obtaining covalent conjugate of oligosaccharide with proteinous support
EP0109942A3 (en) Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
EP0024493A3 (en) Pneumococcal capsular polysaccharide, preparation thereof, multivalent pneumococcal vaccine and method of inducing active immunity
Fattom et al. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen
Rethy Jr et al. The purification-method-dependent immunogenicity of diphtheria toxoid. II. The human immunogenicity of differently purified toxoids.
Schneerson et al. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6 SA polysaccharide-protein conjugates.
ES8206976A1 (es) Procedimiento para la obtencion de una vacuna neumococica

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired